FDA to re-audit Dr. Reddy's Laboratories manufacturing facilities - (livemint.com via NewsPoints Desk)

  • Dr. Reddy's revealed that three facilities that have been sanctioned by the FDA will be re-inspected by the agency in the current quarter, livemint.com reported.

  • "All the commitments as part of warning letter response have been completed," the company said.

  • The sanctions have had a material impact on revenue for the drugmaker, which generated about half of its revenue in the US for the year ended March 2016.

  • Dr. Reddy's currently has 83 products awaiting FDA clearance.

  • Separately, the drugmaker provided an update on its growth strategy, including the planned launch of complex generics, speciality brands and over-the-counter brands in the US and expansion into new markets such as Japan, China and Columbia.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.